Skip to main content

Oral Hemorrhage

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Septodont
SeptodontFrance - Saint-Maur-des-Fosses
1 program
HEMOCOLLAGENE® : Sterile absorbable hemostatic sponges based on bovine collagen - class III MDN/A1 trial
Active Trials
NCT05171231Completed125Est. Mar 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SeptodontHEMOCOLLAGENE® : Sterile absorbable hemostatic sponges based on bovine collagen - class III MD

Clinical Trials (1)

Total enrollment: 125 patients across 1 trials

NCT05171231SeptodontHEMOCOLLAGENE® : Sterile absorbable hemostatic sponges based on bovine collagen - class III MD

Performance and Safety of the Surgical Hemostatic Agent "HEMOCOLLAGENE®" in Patients Requiring Oral Surgery

Start: Nov 2021Est. completion: Mar 2022125 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.